Oczyesa (Octreotide)

Octreotide mimics natural somatostatin and binds to somatostatin receptors, mainly SSTR2 and SSTR5, on endocrine and neuroendocrine cells. This binding inhibits adenylate cyclase, lowers cyclic AMP, and suppresses the release of growth hormone, insulin, glucagon, and other peptide hormones, thereby reducing disease‑driving hormone levels.

The dose of Oczyesa is individualized by the prescribing clinician based on the specific indication, patient weight, response, and tolerability. The prescriber determines the starting dose, titration schedule, and maintenance regimen, so no fixed dosing information is provided here.

Safety data for octreotide in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To order Oczyesa, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

The primary alternative to octreotide is lanreotide, another long‑acting somatostatin analogue. Both agents suppress hormone secretion, but lanreotide is typically administered as a deep‑subcutaneous injection every 4–8 weeks, whereas octreotide can be given multiple times daily or as a long‑acting depot. Choice depends on dosing convenience, patient preference, and specific clinical response.

Oczyesa should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 minutes.

Oczyesa is supplied for subcutaneous injection. The dose is drawn into a sterile syringe and injected into the fatty tissue of the abdomen, thigh, or upper arm using aseptic technique. Patients or caregivers should be trained on proper injection site rotation and disposal of sharps according to local regulations.

Serious adverse events include acute pancreatitis, severe hyper‑ or hypoglycemia, symptomatic gallstone disease or cholecystitis, cardiac arrhythmias, and anaphylactic reactions. Patients should be instructed to seek immediate medical attention if they experience severe abdominal pain, sudden changes in blood sugar, jaundice, chest discomfort, or signs of an allergic reaction.

Oczyesa is contraindicated in individuals with known hypersensitivity to octreotide or any of its excipients. Caution is advised for patients with active gallbladder disease, severe uncontrolled diabetes, or significant cardiac conduction abnormalities. The drug should be used only under medical supervision in these populations.